Docetaxel, Cisplatin, and S-1 (TPS) Induction Chemotherapy in Locally Advanced Head and Neck Cancer

• Status: Completed
• Trial end date: 2012-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study was to evaluate the tolerability and efficacy of a combination of weekly docetaxel, cisplatin, and S-1 (weekly TPS) as induction chemotherapy in patients with locally advanced head and neck squamous cell carcinoma (HNSCC).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chonnam National University Hospital
• Collaborators: Chonbuk National University; Chungbuk National University; Chungnam National University
• Treatments: Cisplatin; Docetaxel

Criteria

Inclusion Criteria:

• locally advanced stage III or IV squamous cell carcinoma of the larynx, oropharynx, or hypopharynx

• ≥18 years old

• absolute neutrophil count ≥1,500/µL, platelets ≥100,000/µL

• serum bilirubin <2.0 mg/dL

• creatinine <1.5 mg/dL

• serum transaminase levels less than twice the upper limit of normal

Exclusion Criteria:

• received previous chemotherapy

• another malignancy

• current or history of distant metastasis

• history of clinically significant cardiac disease within 6 months

• active serious infection

• nasopharyngeal carcinoma

• psychiatric illness that would preclude obtaining informed consent